Cardiovascular risk beyond LDL-C levels: Other lipids are performers in cholesterol story

Postgraduate Medicine

Volumn 116, Issue 3, 2004, Pages 11-15

  Nash, David T ^a,b,c  

^a AMERICAN HEART ASSOCIATION   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c Syracuse Preventive Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; HUMAN; PATIENT CARE; REVIEW;

EID: 4644330584     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2004.09.1584     Document Type: Review

References (14)

1. Ginsberg HN. Lipoprotein physiology. Endocrinol Metab Clin North Am 1998;27(3):503-19
2. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14(11):1767-74
3. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106(4):453-8
4. Krauss RM. Triglycerides and atherogenic lipoptoteins: rationale for lipid management. Am J Med 1998;105(1A):58-62S
5. Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 1990;81(2):470-6
6. Sacks FM, Alaupovic P, Move LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102(16):1886-92
7. Nash DT, Nash SD, Grant WD. Grapeseed oil, a natural agent which raises serum HDL-C levels. Presented at the American College of Cardiology 42nd Annual Scientific Session, Mar 15, 1993, Anaheim, Calif
8. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85(1):37-45
9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Afrairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341(6):410-8
10. Gualandri V, Franceschini G, Sitori SR, et al. AlMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985;37(6):1083-97
11. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001;103(25): 3047-50
12. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17):2292-300
13. Nash DT. Hypercholesterolemia during hospitalization: the case for closer surveillance. Postgrad Med 1986;79(2):303-10
14. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82(1):61-5